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Abstract It was recently demonstrated that dexamethasone
treatment of L6 skeletal muscle cells resulted in an elevation of
GLUT1 protein. However, the level of GLUT4 protein under
these conditions was not examined. In addition, the signalling
mechanism(s) leading to dexamethasone-induced expression of
GLUT1 protein was not investigated. In the present study we
investigated the effect of dexamethasone on the expression of
GLUT1 and GLUT4 proteins in differentiated L6 muscle cells
and the signalling mechanism(s) via which dexamethasone may
act. Dexamethasone (300 nM) treatment for 24 h elevated
GLUT1 and GLUT4 proteins by 68% and 94%, respectively,
above control levels. These increases were due to de novo
synthesis as shown by metabolic labelling with [35S]methionine.
Incubation of cells with 100 nM wortmannin or 30 ng/ml
rapamycin prevented the dexamethasone-stimulated elevation of
GLUT1 protein. In contrast, neither of these inhibitors affected
the elevation of GLUT4 protein by dexamethasone. Further-
more, dexamethasone down-regulated insulin receptor substrate-
1 protein content by 42% and insulin-induced tyrosine phospho-
rylation of insulin receptor substrate-1 by 28%. The p70
ribosomal S6 kinase was not activated by dexamethasone and
instead, dexamethasone attenuated the stimulation of this
enzyme activity by insulin. These results suggest that dexa-
methasone induces the expression of GLUT1 and GLUT4
protein by independent signalling mechanisms with a concomitant
depression of intracellular signalling by insulin.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Dexamethasone, insulin and cellular stressors such as 2,4-
dinitrophenol (an uncoupler of oxidative phosphorylation)
and hyperosmolarity have the common cellular e¡ect of stim-
ulating the expression of the glucose transporter GLUT1 in
L6 skeletal muscle cells [1^3]. Upregulation of GLUT1 pro-
tein synthesis by insulin is completely abrogated by rapamycin
[4] suggesting that in mediating this e¡ect, insulin utilizes a
signalling pathway involving mammalian target of rapamycin
(mTOR). The serine/threonine kinase p70 ribosomal S6 kinase
(p70 S6 kinase) lies downstream of mTOR and its activation
by insulin is also inhibited by rapamycin [5]. Hence, these
results have been interpreted as indicating that insulin induces
GLUT1 protein synthesis by an mTOR/p70 S6 kinase signal-
ling pathway [4]. The molecular mechanisms underlying the
increase in GLUT1 protein expression stimulated by stressors
have been described in a recent study [3]. Hyperosmolarity
induces the expression of GLUT1 via the mTOR/p70 S6 kin-
ase signalling pathway [3] as well as by the mitogen-activated
protein kinase (MAPK)-dependent pathway [3]. In contrast,
there are no studies describing the molecular mechanism(s)
involved in the stimulation of GLUT1 expression by dexa-
methasone.
Understanding the action of dexamethasone on glucose
transporters is attractive since an elevation of GLUT4 protein
level has been demonstrated in skeletal muscle of dexameth-
asone-treated rats [6,7]. An increase in GLUT4 protein has
been suggested to improve insulin sensitivity [8], yet dexa-
methasone also causes insulin resistance in vivo. Interestingly,
the level of GLUT4 protein is not a¡ected by either insulin or
stressors in muscle cells in culture [2,3] while the e¡ect of
dexamethasone on the level of GLUT4 protein in these cells
has not been described.
In the present study we investigated the intracellular signal-
ling mechanisms by which dexamethasone induces the expres-
sion of GLUT1. Secondly, we examined the e¡ect of dexa-
methasone on the expression of GLUT4. We show that 24-h
treatment of L6 skeletal muscle cells with dexamethasone ele-
vated GLUT1 and GLUT4 protein expression. Dexametha-
sone-induced expression of GLUT1 was inhibited by wort-
mannin, an inhibitor of phosphatidylinositol 3-kinase, and
by rapamycin. In contrast, the expression of GLUT4 was
not a¡ected by either wortmannin or rapamycin. Finally, we
show that dexamethasone down-regulated insulin signals.
2. Materials and methods
2.1. Materials
Rabbit antisera containing polyclonal antibodies raised against car-
boxy-terminal sequences of GLUT1 and GLUT4 were obtained from
East Acres Biological Laboratories (Southbridge, MA). Monoclonal
anti-phosphotyrosine antibody and polyclonal antibodies to p70 S6
kinase and insulin receptor substrate-1 (IRS-1) were purchased from
Upstate Biotechnology Inc. (Lake Placid, NY). Anti-p70 S6 kinase
antibody (used to immunoprecipitate for activity assays), PKA and
PKC inhibitory peptides and S6 peptide (RRRLLSSLRA) were from
Santa Cruz Biotechnology (Santa Cruz, CA). The monoclonal anti-
body McK1 to the K1-subunit of the Na/K-ATPase was a kind gift
from Dr. K. Sweadner (Massachusetts General Hospital). Antibodies
used for immunoprecipitating GLUT1 and GLUT4 were previously
described [9]. Protein A-Sepharose was from Pharmacia (Uppsala,
Sweden). [35S]Methionine and [Q-32P]ATP were from Amersham (Oak-
ville, Ont., Canada).
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2.2. Cell culture
A subclone of rat skeletal muscle L6 cells, selected for high fusion
potential was used [10]. To obtain di¡erentiated myotubes for ex-
periments, cells were grown in K-MEM (2% FBS) [10]. For prepara-
tion of lysates the cells were seeded in 12-well plates (1U104 cells/ml)
and prepared as in [11]. Cells were grown in 10-cm dishes (4U104
cells/ml) for preparation of total cellular membranes and p70 S6
kinase activity. Total membranes were prepared as previously de-
scribed [12].
2.3. [35S]Methionine labelling and immunoprecipitation of glucose
transporters
L6 myotubes were treated with or without 300 nM dexamethasone
in K-MEM supplemented with 0.2% (v/v) FBS for 24 h. During the
last 2 h of incubation cells were incubated in methionine-free K-MEM
supplemented with 0.2% (v/v) dialysed FBS in the continued presence
or absence of dexamethasone. During the ¢nal 2 h the cells were
pulsed for 2 h with 200 WCi of [35S]methionine per dish. The labelling
medium was removed, cells were washed twice with ice-cold phos-
phate bu¡ered saline (PBS), solubilized with C12E8 and GLUT1 and
GLUT4 glucose transporters were immunoprecipitated essentially as
described [9].
2.4. p70 S6 kinase activity
L6 myotubes grown in 10-cm dishes were washed twice with ice-
cold PBS and lysed in 1 ml Bu¡er A (50 mM HEPES, pH 7.5, 150
mM NaCl, 20 mM L-glycerophosphate, 10 mM EDTA, 10 mM so-
dium pyrophosphate, 100 mM NaF, 1 mM Na3VO4 and 1% NP-40
(v/v)) containing a mixture of proteinase inhibitors (1 WM leupeptin,
1 WM pepstatin A, 10 WM E64, and 200 WM phenylmethylsulfonyl
£uoride). After 15 min of slow agitation and centrifugation
(15 000Ug for 15 min), the supernatant was subjected to immunopre-
cipitation. p70 S6 kinase was immunoprecipitated using 1 ml of cell
extract and 1 Wg of a rabbit polyclonal p70 S6 kinase antibody. The
protein A-Sepharose complex was washed three times with Bu¡er B
(50 mM Tris-acetate, pH 8, 50 mM NaF, 5 mM sodium pyrophos-
phate, 5 mM L-glycerophosphate, 1 mM Na3VO4; 1 mM EDTA, 1
mM EGTA, 10 nM okadaic acid, 0.1% (v/v) L-mercaptoethanol) in-
cluding all the proteinase inhibitors used above and twice with Bu¡er
C (20 mM 4-morpholinepropanesulfonic acid, pH 7.2, 25 mM L-glyc-
erol phosphate, 5 mM EGTA, 2 mM EDTA, 20 mM MgCl2, 2 mM
Na3VO4 and 1 mM dithiothreitol. p70 S6 kinase activity was assayed
essentially as described [13] in a ¢nal volume of 50 Wl of bu¡er C
containing 1 WM protein kinase A and 1 WM protein kinase C inhib-
itor peptides, 0.2 mM S6 peptide, and 0.25 mM Mg-[Q-32P]ATP at
30‡C for 10 min. Aliquots (30 Wl) were transferred onto Whatman p81
papers and washed 3 times for 15 min with 175 mM phosphoric acid
[14]. 32P incorporated into the S6 peptide was measured by liquid
scintillation counting. One unit of protein kinase activity corresponds
to 1 WM of 32P incorporated into the substrate peptide under the assay
conditions.
2.5. Immunoblotting
Total cell lysates (15 Wg protein) were subjected to SDS-polyacryl-
amide gel electrophoresis on 7% polyacrylamide gels and transferred
onto polyvinylidene di£uoride membranes. Membranes were probed
with anti-phosphotyrosine antibody (1 Wg/ml) followed by sheep anti-
mouse immunoglobulin conjugated to horseradish peroxidase (1:5000
dilution) or probed with anti-IRS-1 (1 Wg/ml) or anti-p70 S6 kinase
(1 Wg/ml) antibodies followed by goat anti-rabbit immunoglobulin
conjugated to horseradish peroxidase (1:5000 dilution). Proteins
were visualized by the enhanced chemiluminescence method.
GLUT1 and GLUT4 levels were determined in total membranes (50
Wg protein) separated on 10% polyacrylamide gels and transferred
onto polyvinylidene di£uoride membranes. Membranes were probed
with anti-GLUT1 (1:2000 dilution) or anti-GLUT4 (1:2000 dilution)
antibodies followed by 125I-labeled protein-A (1 WCi/10 ml). Blots
were visualized by autoradiography using XAR-5 ¢lm (Eastman Ko-
dak, Rochester, NY). Laser scanning densitometry was done using a
PDI model DNA 35 scanner with version 1 of the discovery series
one-dimensional gel analysis software.
2.6. Statistical analysis
Data were compared using either the analysis of variance test
(Fischer, multiple comparisons) or Student’s paired t-test as indicated.
3. Results
3.1. E¡ect of wortmannin and rapamycin on the expression of
GLUT1 stimulated by dexamethasone
Di¡erentiated L6 muscle cells were treated for 24 h with
dexamethasone (DEX) in the absence or presence of 100 nM
wortmannin, an inhibitor of phosphatidylinositol 3-kinase [15]
and total cell membranes were prepared to examine the e¡ect
of this treatment on glucose transporter levels. As shown in
Fig. 1A and quanti¢ed in Fig. 1B, GLUT1 level was increased
by 68% above control in cells treated with DEX. We found
that this increase in GLUT1 protein was blocked by incuba-
tion with wortmannin. To further characterize the molecular
mechanism(s) that may be mediating the e¡ect of dexametha-
sone on GLUT1, we utilized rapamycin. Rapamycin (30 ng/
ml) inhibited the DEX-stimulated increase in GLUT1 protein.
Hence, dexamethasone stimulated the expression of GLUT1
in L6 skeletal muscle cells through a wortmannin- and rapa-
mycin-sensitive pathway.
3.2. E¡ect of wortmannin and rapamycin on the expression of
GLUT4 stimulated by dexamethasone
The e¡ect of DEX on GLUT4 protein level has not been
reported in muscle cells in culture although an elevation of
GLUT4 protein has been demonstrated in skeletal muscle of
glucocorticoid-treated rats [6,16]. It is unknown if this e¡ect is
due to a direct action of DEX on skeletal muscle tissue.
Therefore, we investigated the e¡ect of dexamethasone on
the level of expression of GLUT4 protein in L6 skeletal
muscle cells in culture. Total membranes prepared from
DEX-treated cells had an elevated GLUT4 protein level of
94% above vehicle treated control cells (Fig. 2). However, in
contrast to the results obtained for GLUT1 this was not
blocked by incubation with either 100 nM wortmannin or
30 ng/ml rapamycin.
3.3. Dexamethasone stimulates the synthesis of GLUT1 and
GLUT4
To determine if the elevation of GLUT1 and GLUT4 pro-
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Fig. 1. E¡ect of dexamethasone treatment on GLUT1 protein. L6
muscle cells were incubated with or without 300 nM dexamethasone
(DEX) for 24 h in K-MEM containing 0.2% FBS in the absence (1
Wl/ml DMSO vehicle) or presence of 100 nM wortmannin (WORT)
or 30 ng/ml rapamycin (RAPA). Total membranes were prepared
and subjected to immunoblot analysis as described in Section 2. a:
Representative blot showing the e¡ect of the various conditions on
GLUT1 protein. The content of Na/K-ATPase K1 subunit was
determined to assess equality of protein loading. b: Mean þ S.E. of
four independent experiments showing the content of GLUT1 pro-
tein. Total GLUT1 protein content in control cells in the absence of
DEX was assigned a value of 1.0, and all other values are expressed
relative to it. *Compared to untreated control. Compared to DEX-
treated control (ANOVA).
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tein content induced by DEX were due to de novo synthesis
of glucose transporters, we investigated the ability of DEX to
stimulate the metabolic incorporation of [35S]methionine into
the transporter proteins. As shown in Fig. 3, cells treated
with DEX for 24 h showed increased metabolic labelling of
both GLUT1 and GLUT4. These results indicate that the
elevation of GLUT1 and GLUT4 protein levels observed
with DEX treatment is a direct consequence of increased pro-
tein synthesis.
3.4. E¡ect of dexamethasone on IRS-1 protein level and
phosphorylation
The increased expression of GLUT1 induced by DEX is
reminiscent of the e¡ect of prolonged exposure of cells to
insulin [2,17]. However, it has been demonstrated that DEX
treatment is associated with a down-regulation of insulin re-
ceptor substrate-1 (IRS-1) protein, an immediate downstream
substrate of the insulin receptor [18], in several cell types [19^
21]. To determine if DEX a¡ects insulin signalling events in
di¡erentiated L6 muscle cells we examined whether DEX
treatment altered IRS-1 protein content or its insulin-stimu-
lated tyrosine phosphorylation. DEX treatment for 24 h re-
duced IRS-1 protein content to 57.2 þ 0.07% of the control
levels (Fig. 4) (P6 0.05: Student’s paired t-test). When these
cells were stimulated with insulin for 5 min tyrosine phospho-
rylation of IRS-1 was reduced to 72.4 þ 0.04% of the control
level by DEX treatment (P6 0.05: Student’s paired t-test).
These results suggest that dexamethasone treatment does in-
deed alter the insulin signalling cascade at an early step.
3.5. E¡ect of dexamethasone on p70 S6 kinase activity
The stimulation of GLUT1 protein synthesis by insulin [2]
has been suggested to be mediated by the mTOR/p70 S6 kin-
ase signalling pathway [4]. Rapamycin inhibited the DEX-
stimulated increase in GLUT1 protein (Fig. 1, Fig. 2). This
suggested that DEX may be utilizing the mTOR/p70 S6 kin-
ase pathway. To test this possibility we investigated the ability
of DEX to activate p70 S6 kinase. Cells treated for 30 min or
3 h with 300 nM DEX showed no activation of p70 S6 kinase
(Fig. 5). Intriguingly, in cells treated with DEX for 3 h and
then stimulated with 100 nM insulin for 5 min, DEX actually
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Fig. 4. E¡ect of dexamethasone treatment on IRS-1 protein content
and tyrosine phosphorylation. L6 muscle cells were incubated with-
out (CON) or with 300 nM dexamethasone (DEX) for 24 h in K-
MEM containing 0.2% FBS. Cells were then treated without (Basal,
B) or with 100 nM insulin (I) for 5 min, and IRS-1 protein and ty-
rosine phosphorylation were detected in whole cell lysates as de-
scribed in Section 2. Representative blots for (a) phosphotyrosine
and (b) IRS-1 protein levels are shown. Changes in IRS-1 protein
content and tyrosine phosphorylation of four independent experi-
ments were determined by densitometric scanning and are discussed
in the text.
Fig. 3. E¡ect of dexamethasone treatment on the synthesis of
GLUT1 and GLUT4 proteins. Cells treated for 24 h without (C) or
with 300 nM dexamethasone in K-MEM containing 0.2% FBS were
radiolabelled with [35S]methionine as described in Section 2.
GLUT1 and GLUT4 were immunoprecipitated and resolved on
10% SDS-PAGE. Gels were dried and the amount of 35S-labelled
glucose transporters determined by £uorography.
Fig. 2. E¡ect of dexamethasone treatment on GLUT4 protein. L6
muscle cells were incubated with or without 300 nM dexamethasone
(DEX) for 24 h in K-MEM containing 0.2% FBS in the absence (1
Wl/ml DMSO vehicle) or presence of 100 nM wortmannin (WORT)
or 30 ng/ml rapamycin (RAPA). Total membranes were prepared
and subjected to immunoblot analysis as described in Section 2. a:
Representative blot showing the e¡ect of the various conditions on
GLUT4 protein. The content of Na/K-ATPase K1 subunit was
determined to assess equality of protein loading. b: Mean þ S.E. of
four independent experiments showing the content of GLUT4 pro-
tein. Total GLUT4 protein in control cells in the absence of DEX
was assigned a value of 1.0, and other values are expressed relative
to it. *Compared to untreated control (ANOVA).
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reduced insulin-stimulated p70 S6 kinase activity. There was
no alteration in the total protein content of p70 S6 kinase in
cells treated with 300 nM DEX for up to 24 h (104.2 þ 13% of
control). This is the ¢rst time that the e¡ect of DEX on in-
sulin-stimulated p70 S6 kinase activity has been investigated.
4. Discussion
Glucocorticoids induce a state of insulin resistance when
administered to humans or experimental animals [22]. Studies
in whole animals preclude the assessment of the site of action
of glucocorticoids. It is possible that these hormones act di-
rectly on peripheral tissues resulting in insulin resistance, or
alternatively through changes in the blood levels of glucose,
insulin or fatty acids that occur during glucocorticoid excess.
The use of cells in culture provides a means to focus on the
e¡ect of hormones directly. In the present study we examined
the e¡ect of dexamethasone (DEX) on the expression of the
glucose transporters GLUT1 and GLUT4, in L6 skeletal
muscle cells. We show by metabolic labelling with
[35S]methionine that DEX increased the biosynthesis of
GLUT1 and GLUT4 proteins. In addition, DEX down-regu-
lated two insulin-dependent signals: insulin receptor sub-
strate-1 (IRS-1) phosphorylation and activation of p70 ribo-
somal S6 kinase. We hypothesize that the elevation in GLUT1
and GLUT4 proteins by DEX might be an adaptive response
to the down-regulation of insulin signals.
Rapamycin inhibited the induction of GLUT1 protein by
DEX. This indicates that either mTOR or some downstream
e¡ector that is not necessarily p70 S6 kinase, participates in
this response. DEX did not stimulate p70 S6 kinase activity
(Fig. 5). Therefore the sensitivity to rapamycin could be due
to a direct participation of mTOR itself and not p70 S6 kin-
ase. Brunn et al. [23] have recently demonstrated that the
translational repressor PHAS-I (protein that is heat and
acid stable-insulin responsive) is phosphorylated by mTOR
and the phosphorylation of the latter is inhibited by rapamy-
cin. Phosphorylation of PHAS-I is an important step mediat-
ing insulin-stimulated protein synthesis [24,25]. In addition,
von Manteu¡el et al. (1997) have clearly demonstrated that
PHAS-I and p70 S6 kinase are located on parallel signalling
pathways, downstream of mTOR [26]. Hence, the ability of
rapamycin to inhibit DEX-stimulated expression of GLUT1
protein may implicate the mTOR/PHAS-I pathway. Rapamy-
cin has also been suggested to interfere with signal transduc-
tion from the glucocorticoid receptor by interacting with im-
munophilins that associate with the glucocorticoid receptor
[27]. These immunophilins (several heat shock proteins) facil-
itate proper translocation of the glucocorticoid signalling
complex to the nucleus [28]. This is unlikely in our study since
if rapamycin was interfering with activation of the glucocorti-
coid receptor, then there should not be any preference for the
inhibition of GLUT1 protein expression over GLUT4. How-
ever, the elevation of GLUT4 protein by DEX was not in-
hibited by rapamycin. This indicates that di¡erent pathways
are involved in the regulation of GLUT1 and GLUT4 protein
expression. This is not surprising since Sivitz and Paisley
(1995) demonstrated that GLUT1 mRNA and protein are
elevated by DEX. However, there was no change in the
amount of GLUT4 mRNA. Here we show that GLUT4 pro-
tein increases in response to DEX.
Wortmannin treatment inhibited the stimulation of GLUT1
protein expression by DEX without a¡ecting the DEX-in-
duced expression of GLUT4. DEX treatment reduces IRS-1
associated phosphatidylinositol 3-kinase (PI 3-kinase) activity
in rat skeletal muscle [29] and reduces IRS-1 associated PI 3-
kinase activity stimulated by IGF-1 in L6 muscle cells by 50%
[30]. Hence, DEX is not expected to act via a PI 3-kinase-
dependent pathway to induce GLUT1 protein. The sensitivity
of GLUT1 protein expression to wortmannin may be due to a
non-speci¢c action of wortmannin. Indeed, wortmannin has
been shown to inhibit phospholipase A2 [31], mitogen acti-
vated protein kinases [32], phosphatidylinositol 4-kinase [33],
mTOR autokinase activity [34] and PHAS-I phosphorylation
[23]. We suggest that the observed wortmannin sensitivity
could be due to a direct inhibitory e¡ect on mTOR or the
mTOR-mediated signalling pathway involving PHAS-I.
From the above discussion we conclude that direct exposure
of muscle cells to DEX reduced total IRS-1 protein, impaired
its insulin-dependent tyrosine phosphorylation and reduced
insulin-dependent activation of p70 S6 kinase. In addition,
DEX treatment increased biosynthesis of GLUT1 and
GLUT4 proteins. This action did not utilize known elements
of insulin signalling pathways known to regulate glucose
transporters synthesis. The increased transporter levels may
arise in an attempt to counteract a detrimental e¡ect of
DEX on insulin signal transduction.
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